Abstract 4505
Background
Metastatic primary adrenal tumors include those of cortical origin (ACC) and medullary origin (malignant pheochromocytoma/paraganglioma (MP)). Given the rarity of these cancers, standard treatment options are limited, and outcomes are often dismal. In a previous study of single agent pembrolizumab, the proportion of patients with ACC and MP found to have disease control at 6 months defined as stable disease or better using RECIST v1.1 was greater than 25% of patients. Given the FDA approval of nivolumab and ipilimumab (N+I) with both melanoma and metastatic renal cell carcinoma with enhanced overall response rates (ORR) compared to single agent nivolumab in these diseases we sought to study this combination in rare genitourinary tumors (GU). NCT03333616 is a multicenter, single arm, phase II study of N+I in rare GU tumors including cohorts for ACC and MP, urothelial cancer pure variants, and other rare GU tumors. Herein, we report the preliminary results of the fully accrued adrenal cohort.
Methods
Eligible patients with ACC or MP required measurable disease as defined by RECIST v1.1, an ECOG performance status of 0-2, and may have received any line of prior therapy excluding prior immunotherapy. Hormonal therapy for hormonally active tumors was allowed. Patients underwent a baseline biopsy and received treatment with N 3 mg/kg and I 1 mg/kg intravenously every 3 weeks for 4 cycles with continued maintenance of N 480 mg IV every 4 weeks. The primary endpoint is overall response rate (ORR) by RECIST 1.1. Accrual is complete with 19 patients enrolled into ACC cohort.
Results
The ORR will be reported with 80% CI with all patients completing at least one scan. Secondary endpoints of immune-related toxicity rates will also be presented.
Conclusions
These results will inform the role of immunotherapy combinations in the management of advanced ACC.
Clinical trial identification
NCT03333616.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BMS.
Disclosure
M.T. Campbell: Honoraria (self): Pfizer; Honoraria (self): Genentech; Honoraria (self): Apricity Health LLC; Advisory / Consultancy: EMD Serono, Inc; Advisory / Consultancy: Genentech, Inc. A.Y. Shah: Honoraria (self): Eisai; Honoraria (self): Oncology Information Group; Honoraria (self): Roche Pharmaceuticals; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): BMS; Research grant / Funding (institution): EMD Serono. M.A. Habra: Research grant / Funding (self): Exelixis; Research grant / Funding (self): HRA Pharma. B.A. McGregor: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Seattle Genetics; Honoraria (self), Advisory / Consultancy: Nektar; Honoraria (self), Advisory / Consultancy: Exiles; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: EMD Serono; Honoraria (self), Advisory / Consultancy: Decibel; Research grant / Funding (institution): BMS. M.A. Bilen: Advisory / Consultancy: Exelixis; Advisory / Consultancy: Nektar; Advisory / Consultancy: GenomicHealth; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Sanofi; Research grant / Funding (institution): Bayer; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Genentech/Roche; Research grant / Funding (self): Incyte; Research grant / Funding (self): Nektar; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Tricon Pharmaceuticals; Research grant / Funding (self): Peleton; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract